Sarcomas

César Serrano-García, MD, PhD, highlights ripretinib and the meaningful benefit it provides as a fourth- and later-line therapy in patients with advanced gastrointestinal stromal tumor who harbor KIT or PDGFRA mutations.

John A. Abraham, MD, FACS, discusses remaining questions with pexidartinib in tenosynovial giant cell tumor.

Gina Z. D'Amato, MD, discusses the limitations of liquid biopsy in sarcoma.

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the utility of IDH1/2 inhibitors in chondrosarcoma.

John A. Abraham, MD, FACS, discusses the clinical utility of pexidartinib in tenosynovial giant cell tumor.

Ripretinib continues to show clinically meaningful benefit with an acceptable safety profile when used as a fourth- or later-line treatment for patients with advanced gastrointestinal stromal tumor.

TP53 was found to be the only gene with a germline de novo pathogenic or likely pathogenic variant in pediatric patients with osteosarcoma.

Tazemetostat demonstrated durable responses and sustained safety in patients with epithelioid sarcoma and relapsed/refractory follicular lymphoma.

The survival outcomes of patients with high-grade surface osteosarcoma is poor, despite the use of contemporary treatment with surgery and chemotherapy.

John Zalcberg, ​PhD, OAM, discusses the management of patients with gastrointestinal stromal tumor​.

The presence of macroscopic metastases in regional lymph nodes is found to be related to poor survival outcomes in patients with sarcoma.

The European Commission has granted a conditional marketing authorization to avapritinib for single agent use in adult patients with unresectable or metastatic gastrointestinal stromal tumors that harbor a PDGFRA D842V mutation.

R. Lor Randall, MD, highlights the innovative efforts by the COG, ongoing studies in sarcomas, and how the organization is adapting during a world with COVID-19.

The feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demonstrated in the phase 1b TRAMUNE trial.

Pembrolizumab monotherapy prolonged progression-free survival in selected rare sarcoma subtypes, supporting the immune checkpoint inhibitor’s ability to improve outcomes across histotypes.

Regorafenib extended progression-free survival at 24 weeks compared with placebo for patients with Ewing sarcoma in the phase 2 REGOBONE study. However, the oral multi-kinase inhibitor failed to meet the study’s primary endpoint of non-progression at 8 weeks.

Patricia Pautier, MD, discusses remaining challenges in treating patients with metastatic/advanced uterine and soft tissue leiomyosarcoma.

Patricia Pautier, MD, discusses the rationale for the phase 2 LMS-02 trial, the importance of histologic stratification, and ongoing challenges in soft tissue sarcoma.

Patricia Pautier, MD, discusses the rationale for the phase 2 LMS-02 trial in ​uterine and soft tissue leiomyosarcoma. 

Christina L. Roland, MD, MS, FACS, discusses the results from a phase 2 study evaluating neoadjuvant checkpoint blockade study in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Alessandro Gronchi, MD, discusses the toxicity profile of trabectedin and radiation therapy in patients with soft tissue sarcoma.

The overall use of chemotherapy in high-risk soft tissue sarcomas has been found to be significantly low.

In a special episode of OncLive® On Air, Shiraj Sen, MD, PhD, and Roman Groisberg, MD, highlight research evaluating combination chemotherapy regimens in the evolving sarcoma treatment paradigm.

Jeffery Weitzel, MD, discusses the identification of ​Li-Fraumeni syndrome.

César Serrano-García, MD, discusses the rationale for the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.